GCP
CRL icon

GSA Capital Partners’s Charles River Laboratories CRL Stock Holding History

GSA Capital Partners’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,310
Closed -$242K – 1724
2024
Q4 		$242K Buy
+1,310
New +$252K 0.02% 1324
2020
Q1 		– Sell
-16,572
Closed -$2.53M – 1134
2019
Q4 		$2.53M Sell
16,572
-2,451
-13% -$339K 0.29% 13
2019
Q3 		$2.52M Buy
19,023
+6,297
+49% +$844K 0.34% 8
2019
Q2 		$1.81M Sell
12,726
-3,774
-23% -$512K 0.2% 58
2019
Q1 		$2.4M Buy
16,500
+659
+4% +$86.6K 0.24% 46
2018
Q4 		$1.79M Buy
15,841
+3,564
+29% +$446K 0.21% 69
2018
Q3 		$1.65M Sell
12,277
-5,974
-33% -$737K 0.09% 351
2018
Q2 		$2.05M Sell
18,251
-14,503
-44% -$1.57M 0.1% 265
2018
Q1 		$3.5M Buy
32,754
+823
+3% +$88.7K 0.18% 72
2017
Q4 		$3.5M Buy
31,931
+8,747
+38% +$952K 0.21% 55
2017
Q3 		$2.5M Buy
23,184
+10,544
+83% +$1.08M 0.17% 85
2017
Q2 		$1.28M Sell
12,640
-21,766
-63% -$2M 0.08% 375
2017
Q1 		$3.1M Sell
34,406
-13,485
-28% -$1.15M 0.17% 99
2016
Q4 		$3.65M Sell
47,891
-2,770
-5% -$210K 0.22% 42
2016
Q3 		$4.22M Sell
50,661
-5,485
-10% -$460K 0.23% 35
2016
Q2 		$4.63M Buy
56,146
+1,467
+3% +$121K 0.26% 22
2016
Q1 		$4.15M Sell
54,679
-4,682
-8% -$347K 0.26% 20
2015
Q4 		$4.77M Buy
59,361
+1,209
+2% +$87.2K 0.23% 27
2015
Q3 		$3.69M Sell
58,152
-30,126
-34% -$2.16M 0.18% 75
2015
Q2 		$6.21M Buy
88,278
+42,523
+93% +$3.15M 0.24% 35
2015
Q1 		$3.63M Buy
45,755
+2,842
+7% +$210K 0.14% 108
2014
Q4 		$2.73M Buy
42,913
+15,447
+56% +$968K 0.19% 67
2014
Q3 		$1.64M Sell
27,466
-13,531
-33% -$774K 0.09% 254
2014
Q2 		$2.19M Buy
40,997
+20,667
+102% +$1.13M 0.1% 218
2014
Q1 		$1.23M Sell
20,330
-7,178
-26% -$418K 0.09% 241
2013
Q4 		$1.46M Sell
27,508
-12,486
-31% -$627K 0.12% 179
2013
Q3 		$1.85M Buy
39,994
+18,601
+87% +$854K 0.15% 137
2013
Q2 		$878K Buy
+21,393
New +$917K 0.1% 260

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Impactive Capital New York City, New York $1.4B AUM 13.97% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

GSA Capital Partners's CRL Position: Q1 2025 in Review

GSA Capital Partners sold out of Charles River Laboratories (CRL) in Q1 2025, closing a stake of 1,310 shares — an estimated $242K sold.

GSA Capital Partners first reported a position in CRL in Q2 2013 and held it in 28 quarters. The position peaked at $6.21M in Q2 2015. 561 funds tracked by Wall St. Rank hold CRL as of Q1 2025.

  • GSA Capital Partners reported no remaining Charles River Laboratories position as of Q1 2025 after selling out during the quarter.
  • GSA Capital Partners sold 1,310 Charles River Laboratories shares in Q1 2025, an estimated $242K.
  • GSA Capital Partners first reported a position in Charles River Laboratories in Q2 2013 and held it in 28 quarters.
  • GSA Capital Partners's Charles River Laboratories position peaked at $6.21M in Q2 2015.
  • 561 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2025.

Based on GSA Capital Partners's 13F filing for Q1 2025, filed 8 May 2025.